ICU Medical Inc
Change company Symbol lookup
Select an option...
ICUI ICU Medical Inc
RYT Invesco S&P 500® Equal Weight Technology ETF
VIEIX Vanguard Extended Market Index Fund Institutional Shares
ARCC Ares Capital Corp
EDIT Editas Medicine Inc
SMRT Stein Mart Inc
CBU Community Bank System Inc
BTA BlackRock Long-Term Municipal Advantage Trust
ARCI Appliance Recycling Centers of America Inc
PANXF Platinex Inc

Health Care : Health Care Equipment & Supplies | Mid Cap GrowthCompany profile

ICU Medical, Inc. is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. The primary critical care products it manufactures are Hemodynamic Monitoring Systems, SafeSet Closed Blood Sampling and Conservation System, Transpac Consumable Blood Pressure Transducers and Other Critical Care Products. The primary oncology products it manufactures are ChemoLock Needlefree CSTD, ChemoClave Needlefree CSTD and Diana Hazardous Drug Compounding System. As of December 31, 2016, its products were used in acute care hospitals and ambulatory clinics in more than 65 countries throughout the world.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Bank of America shares edge lower as first-quarter revenue falls short

7:02 am ET April 16, 2019 (MarketWatch)

Bank of America Corp. (BAC) said Tuesday it had net income of $7.3 billion, or 70 cents a share, in the first quarter, up from $6.9 billion, or 62 cents a share, in the year-earlier period. Revenue edged down to $23.0 billion from $23.1 billion. The FactSet consensus was for EPS of 66 cents and revenue of $23.2 billion. Net interest income rose 10% to $$629 million, driven by higher interest rates and growth in deposits and loans. The company's loan book grew 5% to $292 billion, while its deposit base rose 3% to $697 billion. Loan loss provisions rose by $179 million to $1.0 billion. The company's trading reveneu fell 17% to $3.5 billion. FICC revenue fell 8% to $2.4 billion and equity trading fell 22% to $1.2 billion. "It was a challenging capital markets environment but our team and platform are optimized to serve clients and generate stable revenues across a range of market conditions over time," Chief Executive Brian Moynihan said in a statement. "We reduced expenses by four percent from the first quarter of 2018, contributing to the seventeenth consecutive quarter of positive operating leverage." The consumer banking division had net income of $3.2 billion, up 25% from a year ago. The global wealth and investment banking division had net income of $1.0 billion, up 14%. The global markets division had net income of $1.0 billion, down 26%, hurt by lower investment banking fees and falling trading revenue. Shares were down 0.3% in premarket trade and have fallen 0.3% in the last 12 months through Monday, while the S&P 500 has gained 8.5%.

-Ciara Linnane; 415-439-6400;

(END) Dow Jones Newswires

April 16, 2019 07:02 ET (11:02 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.